


OneRNA®: RNA Platform for Next Generation Cures



Company Stage: Commercial
Regulatory: CLIA and FDA EUA on COVID-19 PCR Test

Patents: Patents pending, trademarks and trade secrets, proprietary algorithms

Management:
Gitte Pedersen, CEO and Cofounder
Morten Pedersen, PhD, CTO and Cofounder
Jesper Zeuthen, PhD, CMO
Bill Southworth, VP Data
Charles Svitlik, Lab Director

Website:
genomicexpression.com

Product Video: <http://bit.ly/OneRNAMovie>

Literature:
Clinical RNA sequencing in oncology: where are we? <http://bit.ly/ClinicalRNAseq>

Poster ASCO-SITC <http://bit.ly/ASCO-SITC>

Poster in TNBC <http://bit.ly/TNBCPOSTER>

Grants:
• Danish Innovation Fund
• Eurostars
• Horizon2020



Contact:
partner@genomicexpression.com
100 Cummings Cntr, Suite 451C
Beverly MA 01915
USA

“By analyzing RNA we can monitor health, discover disease and design next generation cures!”

OneRNA®: identification and quantification of all mRNA



Clinically validated RNA-sequencing analyzed on proprietary cloud based, HIPAA and GDPR compliant bioinformatics platform:

- 1) Provide patients with actionable treatment options and clinical trials
- 2) Expand drug label for approved oncology drugs
- 3) Rational design combination umbrella or basket trials
- 4) Stratify patients into trial arms
- 5) Develop companion diagnostics/response algorithms
- 6) Design next generation personal cancer treatments

OneRNA® can get from sample to answer in less than a week and works with FFPE, FF, blood, urine, saliva.

The OneRNA® analytics platform can also use standard RNA sequencing data as input data to generate an actionable report



OneRNA® Report: from Sample to Actionable Report

Shipping kit: Preserves total RNA extracted from the tumor that can be shipped by mail at ambient temperatures FFPE, FF, Saliva, Blood, Urine

Sample preparation method: Clinically Validated Chemistry for RNA extraction and sequence library generation that simultaneously identify and quantify +20,000 human transcripts per samples for sequencing on Illumina HiSeq, NextSeq, or MiSeq. OneRNA® chemistry will also be available as a kit.

Bioinformatics: Fast generation of expression profiles from raw sequencing data using proprietary mapping algorithms and novel ways to mine data accessed through HIPAA and GDPR compliant cloud platform.

Database of actionable expression biomarkers: Contains drug targets and gene expression signatures linked to cancer therapies in clinical trials including all immune therapy targets.

OneRNA® report: A clinically actionable report that includes significantly overexpressed and underexpressed cancer drug targets including novel immune therapy targets, and expression biomarkers used in active clinical trials.

Biobank: For larger projects we establish public private partnerships that can include access to the biobank in the world with 15 million fully consented and annotated samples.

Genomic Expression Partnerships and Collaborations

Platform for Next Generation Diagnostics and Cures

Panel free sample prep
Proprietary



World largest biobank
15 million samples



Electronic Medical Records
15 years in single payer



OneRNA™ Report
Proprietary



OneRNA™ Report														
ANALYST Name: [Name] Order Number: [Number] Date: [Date] Requested by: [Name] Requested by Title: [Title]	TESTS ORDERED Test Name: [Name] Test Code: [Code] Test Description: [Description]	PATIENT INFO Patient Name: [Name] Patient ID: [ID] Date of Birth: [DOB] Sex: [Sex] Race: [Race]												
SUMMARY This report provides a summary of the results of the tests ordered. The results are presented in a table below. The results are presented in a table below.														
TEST RESULTS <table border="1"> <thead> <tr> <th>Test Name</th> <th>Result</th> <th>Reference Range</th> </tr> </thead> <tbody> <tr> <td>Test 1</td> <td>Result 1</td> <td>Reference Range 1</td> </tr> <tr> <td>Test 2</td> <td>Result 2</td> <td>Reference Range 2</td> </tr> <tr> <td>Test 3</td> <td>Result 3</td> <td>Reference Range 3</td> </tr> </tbody> </table>			Test Name	Result	Reference Range	Test 1	Result 1	Reference Range 1	Test 2	Result 2	Reference Range 2	Test 3	Result 3	Reference Range 3
Test Name	Result	Reference Range												
Test 1	Result 1	Reference Range 1												
Test 2	Result 2	Reference Range 2												
Test 3	Result 3	Reference Range 3												

Background: Genomic Expression was the diagnostic partner in Denmark’s first large sequence based project called “Genome Denmark”. The project was funded by the Danish Innovation Fund with \$32 million. The OneRNA® technology and vision was created as a result of this public private partnership.

Opportunity for Pharma: 1) Expand the label and IP protection for existing drugs 2) Assist in the development of effective clinical strategies 3) Increase enrollment into clinical studies 4) Design next generation cures.

Clinical Programs: Funded clinical programs in oncology, data from 2 studies in Women’s cancer: breast and ovarian cancer to be published in 2021. Moving COVID-19 to self collection in saliva and leveraging the NGS platform to massively scale COVID-19 testing to enable population screening possible to +100,000 tests/day.

Other indications : The assay is portable into other clinical indications with modifications to the bioinformatics backend. This solves a key problem in bringing clinical relevant markers into clinical practice by adding clinical relevant markers to the report without having to revalidate the assay.

Existing partnerships: [Rutgers Cancer Institute](#), [Nation Cancer Institute \(NCI\)](#), [The Danish Cancer Society](#), [OvaCure](#), [The Val Skinner Foundation](#), [Yale/SalivaDirect](#)

Awards: #2 in the Women’s Founders Pitch event, Top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Tech Challenge Top 5 diagnostic companies at the Molecular Tri-Conference, Top 100 on Red Herring list. Won the Lyfebulb award and the EIC life science pitch competition. Presented at GSTIC, the UN and the European Commission. Semifinalist XPRIZE for Rapid COVID19 testing and finalist GuideWell for better COVID19 solutions.

Management: Gitte Pedersen, CEO is a former executive from Novo Nordisk. She successfully developed and launched multiple products into multiple industries world wide. She was an advisor to the Danish Government, and a number of Biotech companies, where she structured several deals with big pharma such as Merck, Takeda, GSK, Wyeth and others. Morten Pedersen, CTO, PhD has a very strong innovation track record with multiple commercialized product e.g. from Chr Hansen. He is the inventor of the technologies. Jesper Zeuthen, CMO, is the co-founder of GeneMap, and established the Danish Cancer Society. Bill Southworth, VP Data, MIT, creator of products. Been CEO and Vice President of Engineering and Marketing for public and private companies. Coder at heart. Charles Svitlik, Lab Director, established and run several clinical labs under CLIA.